EMA recommends 10 medicines for approval in October meeting
Ten medicines have been recommended for marketing authorisation and 10 extensions of indication have been suggested by the EMA.
List view / Grid view
Ten medicines have been recommended for marketing authorisation and 10 extensions of indication have been suggested by the EMA.
Researchers have revealed the top 10 drugs by annual revenue in 2025. Here, we investigate the indications that necessitate these treatments and the delivery systems they employ.
The FDA grants Orphan Drug Designation to treatments for rare diseases in R&D; here are the 10 most recent for oncologic conditions.
The EMA has suggested seven treatments to be granted marketing authorisations and also advocated indication extension for eight drugs.